Hunter syndrome, an X-linked metabolic storage disorder with a reported incidence between one in 34 000 and one in 162 000, [1] [2] [3] [4] is due to deficiency of iduronate sulfatase enzyme activity. A member of the mucopolysaccharidosis (MPS) family of lysosomal diseases, MPS II evidences a wide spectrum of clinical severity ranging from the early onset severe form (MPS IIA) to the more insidious form, namely MPS IIB. 5 Boys with MPS IIA exhibit significant somatic features such as coarse facies, progressive hearing loss, hepatosplenomegaly, cardiomyopathy, dysostosismultiplex, macrocephaly, central nervous system deterioration, and neuropsychological impairments. As in Hurler syndrome, cribiform (multicystic) changes reflecting storage material in the perivascular Virchow-Robin spaces are noted, particularly in white matter, corpus callosum, and basal ganglia. 6 The disease is also associated with general atrophy, ventriculomegaly, increased signal in basal ganglia, thalamus and brainstem, and increased periventricular signal in white matter. 7 Neuropsychological consequences of MPS IIA are similar to those of Hurler syndrome, except that many behavioral abnormalities such as hyperactivity and aggression are also present. 8 In general, males with MPS IIB experience milder signs and symptoms with great variability in age of onset and severity.
Transplantation using bone marrow, umbilical cord blood, or peripheral blood hematopoietic cells has been effective treatment for selected lysosomal and peroxisomal inherited metabolic storage diseases such as Hurler syndrome, [9] [10] [11] Maroteaux-Lamy, 12 X-linked adrenoleukodystrophy, 13 metachromatic leukodystrophy 14 and globoid-cell leukodystrophy. 15 Consideration of hematopoietic cell transplantation (HCT) and its implementation for these metabolic diseases must take into account the natural history of the disease and its status at HCT, likelihood of achieving stabilization or improvement in somatic and/or neuropsychologic parameters, and the probability of survival with the transplant. Of particular concern to transplanters, neurologists and geneticists has been the effect of the disease on the central nervous system and the prospects for amelioration due to the significant morbidity and mortality of HCT. Furthermore, the likelihood of a fatal disease complication occurring within several months to as long as 5 years accompanied by deteriorating quality of life has been a major motivating force for patients, families and their physicians to accept the significant 'up-front' risks of HCT.
In this issue of Bone Marrow Transplantation, Mullen et al 16 describe a 10-month-old boy with MPS IIB who was transplanted with unrelated umbilical cord blood and achieved full donor-derived engraftment. The course was complicated by bacteremia, mucositis, limited gastrointestinal hemorrhage, grade III skin and grade II gastrointestinal GVHD, and severe autoimmune hemolytic anemia requiring 2 years of steroid and other significant immuno-suppressive therapy. HCT for this patient and others with MPS IIB raises several ethical issues that will be briefly discussed.
Mild Hunter syndrome, MPS IIB, is associated with a life expectancy ranging from 15 years to more than 40 years. 5 The field of HCT for mucopolysaccharide inherited metabolic storage diseases dates to 1980. 9 HCT does not appear to alter the downward course of MPS II with respect to neuropsychological function. 17 Of the cases followed by the North American Storage Disease Collaborative Study Group, all children with MPS IIA have been treatment failures, ie the child's IQ fell below 50 a year or more after HCT. In contrast, arrest of neuropsychological and physical decline was described in a case of MPS IIA 18 and in two cases of MPS IIB. 19, 20 No alternative effective treatment is available. However, ongoing studies are examining the feasibility of gene transfer for individuals with MPS II. 21, 22 There are important ethical considerations surrounding HCT for inherited metabolic storage diseases, in general, and for MPS II specifically. Ethical decision-making in medicine focuses on the autonomy of the patient, the avoidance of harm (primum non nocere, the principle of nonmaleficence), the provision of benefits (the principle of beneficence), and the rule of justice. In the field of HCT for inherited metabolic storage diseases, candidates for this intensive treatment are often minors and/or have limited ability to make decisions due to impaired neuropsychological function and judgment. In the case of MPS IIB, the intellectual function of the patient is relatively preserved and the onset of significant somatic complications occurs relatively late, often in the second decade or later. For children less than 8 years of age, parents or guardians must take full responsibility for deciding to proceed with HCT. From 8 to 17 years of age, the child is afforded the opportunity to assent to the procedure and the parents are asked to provide consent. While generally not considered autonomous, children and adolescents can participate to varying degrees in the process of important medical decision-making, including end of life decisions. 23 Nonmaleficence is a strongly held principle in clinical medicine and a cornerstone in decision-making. In the case of MPS IIB and the use of HCT, a prudent, ethical choice must take into account the risks of transplant as well as the likelihood of extending benefits to the patient if donor-derived engraftment occurs. In the absence of significant HCT experience and follow-up for MPS IIB and the wide range of clinical severity of this disorder, the physician is not able to accurately assess the real or anticipated benefits accruing from successful HCT. A reasonable person might argue that if HCT is to be considered for MPS IIB it should be offered to older patients (ie 8 to 17 years) at a time when they could assent to the procedure since it is unlikely that the disease process will lead to fatal complications during the first two decades of life. One might argue that, when possible and feasible, HCT should be postponed until the patients can participate more fully in the decision-making process. The case presented by Mullen et al focused on the early cardiac death of the patient's maternal uncle. It was reasoned that HCT, if successful, could prevent this fatal complication and also enhance the patient's quality of life. It is observed in long-term survivors of HCT for MPS I that, while cardiac function stabilizes, valvular abnormalities can and do progress despite successful HCT (Elizabeth Braunlin, personal communication). This observation further underscores the question of how beneficial HCT will be to this MPS IIB patient.
For all patients with inherited metabolic storage diseases, the decision-making process regarding HCT continues to pose significant problems and ethical concerns. Due to the limited number of patients and their length of follow-up, careful disease-specific data collection is critical so that, through an international database, HCT outcomes will be readily available to physicians, families and patients faced with these difficult choices.
